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Noninvasive prenatal diagnosis of 
21-Hydroxylase deficiency using 
target capture sequencing of 
maternal plasma DNA
Dingyuan Ma1, Yuan Yuan2,3,4, Chunyu Luo1, Yaoshen Wang  2,3,4, Tao Jiang1, Fengyu Guo2,3,4, 
Jingjing Zhang1, Chao Chen2,3,4, Yun Sun1, Jian Cheng1, Ping Hu1, Jian Wang4,5, Huanming 
Yang4,5, Xin Yi4, Wei Wang2,3,4, Asan2,3,4 & Zhengfeng Xu1
Here, we aimed to validate a noninvasive method using capture sequencing for prenatal diagnosis 
of congenital adrenal hyperplasia due to 21-Hydroxylase deficiency (21-OHD). Noninvasive prenatal 
diagnosis (NIPD) of 21-OHD was based on 14 plasma samples collected from 12 families, including 
four plasma sample collected during the first trimester. Targeted capture sequencing was performed 
using genomic DNA from the parents and child trios to determine the pathogenic and wild-type alleles 
associated with the haplotypes. Maternal plasma DNA was also sequenced to determine the fetal 
inheritance of the allele using hidden Markov model-based haplotype linkage analysis. The effect of 
fetal DNA fraction and sequencing depth on the accuracy of NIPD was investigated. The lower limit 
of fetal DNA fraction was 2% and the threshold mean sequence depth was 38, suggesting potential 
advantage if used in early gestation. The CYP21A2 genotype of the fetus was accurately determined 
in all the 14 plasma samples as early as day 1 and 8 weeks of gestation. Results suggest the accuracy 
and feasibility of NIPD of 21-OHD using a small target capture region with a low threshold for fetal 
DNA fraction and sequence depth. Our method is cost-effective and suggests diagnostic applications in 
clinical practice.
Congenital adrenal hyperplasia (CAH) is caused by the deficiency of enzymes associated with cortisol synthesis. 
CAH is a hereditary and an autosomal recessive disease with an incidence of 1 in 10,000 to 1 in 15,000 at birth1. 
Approximately, 90% to 95% of CAH is caused by CYP21A2-related 21-hydroxylase deficiency (21-OHD), which 
leads to increase in adrenal androgen levels. The affected female is virilized or manifests sex reversal, and the 
affected male displays sexual precocity. Based on the differences in clinical phenotype, this disorder is classified 
into three types: simple virilizing (SV), salt wasting (SW), and non-classical CAH. The salt wasting type is most 
severe, and is associated with hyponatremia, hyperkalemia, acidosis, and hypoglycemia. Death due to circulatory 
failure may occur in the absence of prompt medical intervention2.
Prenatal diagnosis facilitates detection of affected fetuses in high-risk families for appropriate medical man-
agement. Dexamethasone is indicated in affected females to minimize genital virilization3. Prompt medical atten-
tion of the affected newborns is essential. However, prenatal diagnosis performed via invasive methods, such 
as chorionic villus sampling (CVS) and amniocentesis, increase the risk of miscarriage or infection. Recently, 
many noninvasive prenatal diagnostic methods have been developed to detect fetal genetic status using cell-free 
fetal DNA (cff-DNA) in maternal plasma4–7, for e.g., noninvasive prenatal detection of fetal aneuploidy8–10, 
sex-linked genetic diseases11, 12, and autosomal recessive diseases13–16. We have successfully reported noninva-
sive prenatal diagnosis (NIPD) of fetal CYP21A2 genotype using a combination of target capture sequencing 
and haplotype-assisted analysis17. However, the target region in our previous study spanned the whole exome, 
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and 1 million tag single nucleotide polymorphism (SNP) were captured for sequencing analysis, which may be 
expensive and low sensitivity for clinical application. New et al. reported that target capture sequencing of a 6 Mb 
region flanking CYP21A2, facilitated noninvasive genotype analysis of fetus in CAH using relative haplotype 
dosage (RHDO) analysis18. These studies demonstrated that target capture sequencing can be used in noninvasive 
prenatal diagnosis of fetal CAH. However, the large targeted region increases sequencing costs, which may limit 
its routine clinical application.
In this study, we showed that noninvasive prenatal testing (NIPT) of fetal 21-OHD can be accomplished 
by analyzing a 274.15 kb targeted region, including CYP21A2 and 1607 surrounding highly heterozygous SNPs 
distributed within 2 Mbp chromosome 6 region. Inclusion of the chromosome Y-specific sequences in the target 
region facilitates the simultaneous determination of fetal gender. Our approach suggests an affordable strategy for 
clinical application of NIPT of monogenic diseases such as 21-OHD.
Results
Baseline data of recruited families. The clinical demographics of the studied families are shown in 
Table 1. The types of pathogenic mutations identified in the 12 families included point mutations, large-scale gene 
deletions and conversions. Plasma samples were collected twice in the two families, and only once in the other 10 
families. The plasma samples in family F-02 were collected in two pregnancies, respectively. In the family F-04, the 
plasma samples were collected during the first and second trimesters in one pregnancy, respectively. Four out of 
the 14 plasma samples were collected during the first trimester (ranging from 8 weeks and 1 day to 12 weeks and 2 
days), 10 were collected during the second trimester (ranging from 16 weeks and 4 days to 19 weeks and 2 days). 
All the parents were carriers, 11 children used for haplotype constuction were patients, and one child was normal. 
The amniocentesis was performed in all the fetuses to sample fetal genomic DNA (gDNA) for invasive molecular 
diagnosis at 18 weeks and 1 day to 22 weeks and 2 days.
Effect of fetal DNA fraction and sequencing depth on the accuracy of NIPT. To investigate the 
effect of fetal DNA fraction and sequencing depth on the accuracy of our method, we prepared a series of artificial 
mixtures by mixing the maternal gDNA from family F-02’s and paired fetal gDNA derived from the first preg-
nancy. Capture sequencing was performed on the samples of parental gDNA, their first child’s gDNA, the fetal 
gDNA and the artificial mixtures. An average sequencing depth of 268.91 was obtained in these samples (range, 
166.63–406.58), with a mean of approximately 99.5% region covered by at least 20 reads. An average of 1.02 
million reads (range, 0.79–1.27 million) was mapped to the target region for the artificial samples (Supplemental 
Table S2). The estimated fetal DNA fractions were 0.94%, 2.16%, 3.15%, 4.08%, and 9.08%, respectively, cor-
responding to the expected fetal DNA fraction. Using the allele distribution data at each informative SNP site 
and the SNP linkage relationship obtained from parental haplotypes, a hidden Markov model (HMM) was con-
structed to calculate the logarithmic odds ratio of transmission probability between the mutant Hap 0 and the 
wild-type Hap 1 for determined which haplotype is overrepresented in each artificial sample. In the process of 
decoding the HMM chain, the Viterbi algorithm was used to search for the most probable sequence of hidden 
Family No.
Pathogenic mutation in CYP21A2 gene
Plasma sample
Plasma sample 
collection
Amniotic fluid 
collectionFather Mother Child
F-01 Del/WT p.Arg356Trp/WT p.Arg356Trp/Del F-01 plasma 19 wk + 2 d 19 wk + 2 d
F-02 Del/WT IVS2-13A/C > G/WT IVS2-13A/C > G/Del
F-02-F plasma  
(first pregnancy) 19 wk + 1 d 19 wk + 1 d
F-02-S plasma 
(second pregnancy) 18 wk + 5 d 18 wk + 5 d
F-03 IVS2-13A/C > G/WT p.Ile172Asn/WT IVS2-13A/C > G/p. Ile172Asn F-03 plasma 16 wk + 4 d 19 wk + 5 d
F-04 p.Ile172Asn/WT Chimera CH-2/WT p.Ile172Asn/Chimera CH-2
F-04-8 wk plasma 
(first trimester) 8 wk + 1 d
F-04-18 wk plasma 
(second trimester) 18 wk + 3 d 18 wk + 3 d
F-05 IVS2-13A/C > G + promoter conversion Del/WT
IVS2-13A/C > G + promoter 
conversion/Del F-05 plasma 16 wk + 6 d 18 wk + 2 d
F-06 Del/WT p.Ile172Asn/WT p.Ile172Asn/Del F-06 plasma 19w 20 wk + 6 d
F-07 Del/WT IVS2-13A/C > G/WT IVS2-13A/C > G/Del F-07 plasma 10 wk + 3 d 20 wk + 1 d
F-08 IVS2-13A/C > G/WT p.Ile172Asn/WT IVS2-13A/C > G/p. Ile172Asn F-08 plasma 10 wk + 4 d 19 wk + 4 d
F-09 p. [Ile172Asn; Arg356Trp]/WT IVS2-13A/C > G/WT IVS2-13A/C > G/p. [Ile172Asn; Arg356Trp] F-09 plasma 12 wk + 2 d 22 wk + 2 d
F-10 p.Arg484ProfsX40/WT Del/WT p.Arg484ProfsX40/Del F-10 plasma 18 wk + 1 d 18 wk + 1 d
F-11a p.[Gln318X; Arg356Trp]/WT Chimera/WT WT/WTa F-11 plasma 18 wk + 5 d 18 wk + 5 d
F-12 Partial conv/WT IVS2-13A/C > G/WT IVS2-13A/C > G/Partial conv F-12 plasma 18 wk + 6 d 19 wk + 5 d
Table 1. Overview of the studied families. aThe parents were referred to our clinic for prenatal diagnosis 
because their first two children died shortly after birth due to CAH. Abbreviantions: WT: wild-type allele; 
Chimera: CH-2, which possesses the CYP21A1P gene from exon 1 to exon 4; Partial conv: Cluster E6, 
p.Val281Leu, p.Leu307PhefsX6, and p.Arg356Trp mutations.
www.nature.com/scientificreports/
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states. Haplotype analysis revealed that 830 SNPs were informative for paternal haplotype deduction and 534 
SNPs were informative for maternal haplotype deduction in this family. The inferred fetal haplotypes from the 
HMM are shown in Fig. 1. For paternal haplotype inheritance, the logarithmic odds ratio curves are similar at 
different fetal DNA fractions. It is the same with maternal haplotype inheritance. An odd ratio above the x axe 
is classified as an allele belong to the mutant Hap 0, whereas an odd ratio below the x axe is classified as an allele 
belong to the wild-type Hap 1. In 2 Mbp genomic region around the CYP21A2 gene, the fetus inherited the 
mutant Hap 0 from both parents respectively. These results demonstrated that this approach is robust to the fetal 
DNA fraction. The scatterplot of the frequency of Hap 0 alleles of the fetus is also shown in Fig. 1. For paternal 
inheritance, the frequency of the paternal allele (the father is heterozygous) is around half of fetal DNA fraction 
if it is different from the maternal allele (the mother is homozygous). Conversely, if the paternal allele is the same 
as the maternal allele, it’s frequency is 100%. For maternal inheritance, the frequency of the maternal allele (the 
mother is heterozygous) is around 50% whether or not it is the same as the paternal allele (the father was homozy-
gous) because fetal DNA represents only a small fraction of the total maternal plasma DNA. The scatterplot 
couldn’t give us reliable information about the fetal haplotypes because of site-to-site variability.
The effect of sequencing depth was studied by randomly sampling different numbers of mapped reads for 
each artificial sample. The statistical and estimated fetal DNA fractions for each artificial data are shown in 
Supplemental Table S3. A series of simulation data with an average depth of 38.09, 60.25, 110.06, 164.91 and 
219.99 were obtained for each artificial mixture with different fetal DNA fraction. For 30× and 50× simulation 
of 1% fetal DNA fraction artificial mixture, the fetal DNA fractions were too low (0% and 0.5%) to perform 
haplotype analysis. The results showed that for simulation samples with fetal DNA fraction of 1%, the maternal 
haplotype could not be correctly determined at any simulation depth. When the fetal DNA fraction reached 2%, a 
mean sequence depth higher than 38 was adequate to correctly deduce both the paternal and maternal haplotype 
inheritance (Table 2 and Supplemental Figures S1–S5).
Plasma sequencing data. The baseline data of each plasma sample are shown in Supplemental Table S4. 
For genomic DNA samples, the mean depth of region of interest was approximately 183 (range, 73–307) after 
filtering the duplicate reads, with approximately 96% covered by at least 20 reads. For plasma DNA samples, 
an average of 1.68 million reads (range, 0.47–2.63 million) was mapped to the target region, the mean depth of 
region of interest was approximately 223 (range, 91–339) after filtration of the duplicate paired-end reads, with 
approximately 99.38% region covered by at least 20 reads.
Estimation of fetal DNA fraction. The fetal DNA fraction in plasma ranged from 5.5% to 15.54% 
(Table 3). No significant differences were found between the first trimester plasma samples (mean, 8.74%; range, 
5.84–12.00%) and the second trimester plasma samples (mean, 10.11%; range, 5.50–15.54%). In the family 4, the 
fetal DNA fraction in the first trimester (8 wk + 1 d) sample was 7.82%, which increased to 8.15%, in the second 
trimester sample (18 wk + 3 d). The high fetal DNA fraction observed in the first trimester plasma sample may be 
attributed to individual difference.
Noninvasive determination of fetal sex. The fetal sex was determined using the mean depth and 4× 
coverage of target region in chromosome Y in the plasma samples (Supplemental Table S4). In the paternal gDNA 
samples, the mean depth of target region in chromosome Y ranged from 180× to 497×, and a mean of 99.9% 
region was covered by at least 4 reads (range, 98.6–100%). In the maternal gDNA samples, the mean depth and 
4× coverage of chromosome Y specific region were extremely low, indicating that the fetal sex could be deter-
mined using the two parameters. In the families F-05, F-06, F-09, F-10, F-11, the mean depth of target region in 
chromosome Y was 59.9 (range, 32.19–76.04), with a mean of 99.20% region covered by at least four reads (range, 
97.31–100%), indicating a male fetus in the pregnancy. In the other families, the mean depth of target region in 
chromosome Y ranged from 2.04 to 11.75, and the 4× coverage ranged from 5.57% to 24.22%, indicating that the 
fetuses were female. These results were confirmed by the sequencing data of fetal genomic DNA.
Noninvasive prenatal diagnosis of fetal 21-OHD. We sequenced 14 plasma DNA samples derived 
from 12 pregnant women. The sequence data showed high coverage over the region of interest in each sample 
(Supplemental Table S4). The fetal DNA fraction and sequencing depth of each plasma sample met the require-
ments for accurate analysis in the simulation samples. An average of 2195 SNPs around the region flanking the 
CYP21A2 gene was detected in each of the gDNA samples (Supplemental Table S5). After basic data analysis and 
SNP calling, parental haplotypes were constructed by trio analysis (analysis of genotypes of the mother, father, 
and child). The number of informative phased SNPs used for NIPT of 21-OHD ranged from 1104 to 1979 for each 
family (Table 3). With the assistance of the parental haplotypes, we recovered fetal haplotypes using the HMM 
using the allele distribution data at informative SNP sites of maternal plasma DNA. The HMM-based prediction 
of fetal haplotype is shown in Table 3. In order to visualize the prediction results of the HMM, the logarithmic 
odds ratios of transmission probability between Hap 0 alleles and Hap 1 alleles were calculated at each informa-
tive SNP site in 2 Mbp genomic region around the CYP21A2 gene. These values were then plotted against chro-
mosome position in Fig. 2. Using the first pregnancy sample of family F-02 as an example, involving the genomic 
region around CYP21A2, 1364 SNPs were successfully phased with 830 SNPs to deduce paternal inheritance 
and with 534 SNPs for maternal inheritance. Mat-Hap 0 was linked to CYP21A2 deletion, and Pat-Hap 0 was 
linked to IVS2-13A/C > G mutation. The prediction revealed that the fetus inherited the pathogenic haplotype 
from both the parents. Thus, the fetal genotype was IVS2-13A/C > G/Del, which was affected by CAH. During 
the second pregnancy of F-02, the prediction revealed that the fetus inherited the paternal pathogenic haploytpe 
and the maternal wild-type haplotype, suggesting a carrier with Del/WT genotype. In the 11 remaining samples, 
six fetuses were predicted to be carriers, and five manifested CAH. In the family 4, similar results were obtained 
www.nature.com/scientificreports/
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from plasma samples collected at 8 wk + 1 d and 18 wk + 3 d. Amniocentesis was conducted for routine clinical 
diagnosis of all the fetuses, and the results were consistent with noninvasive diagnosis.
Discussion
NIPD of monogenic disease is an important clinical goal. It provides requisite prognostic data for clinical inter-
vention. However, in most reported cases, the targeted region for fetal genotype analysis is relatively large, and the 
cost of sequencing is exorbitant. In this study, we demonstrated the feasibility of NIPD of CAH due to 21-OHD 
by sequencing a much smaller region. The fetal genotypes were successfully determined from 14 plasma samples 
Figure 1. Fetal genotype determination in artificial mixtures. The inheritance of paternal haplotype is displayed 
on the left, and inheritance of maternal haplotpe on the right. Hap 0 was linked to the pathogenic mutation in 
CYP21A2, while Hap 1 was linked to wild-type allele. The red points represent the frequency of Hap 0 alleles 
at each informative SNP site. The black lines indicate haplotype inheritance by the fetus. The logarithmic odds 
ratio of transmission probability between Hap 0 and Hap 1 was calculated by P0*P0re/(P1*P1re), where P0re is 
the probability of recombination during fetal inheritance Hap 0, and P1re is the probability of recombination if 
fetus inherited Hap 1.
www.nature.com/scientificreports/
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obtained from 12 21-OHD families. Based on our previous data17, we extensively redesigned and optimized cap-
ture probes for targeted sequencing. The target region used for 21-OHD analysis comprised only 274.15 kb, con-
taining the whole CYP21A2, highly heterozygous SNPs distributed within 2 Mbp genomic region flanking the 
CYP21A2 gene, and the chromosome Y-specific region. Our probe design provided a solution for decreasing the 
cost of next generation sequencing by increasing the proportion of available data. The high homology between the 
CYP21A2 gene and the CYP21A1P pseudogene is the major obstacle to a faultless CYP21A2 genotyping. 21-OHD 
is genetically caused by a variety of mutations in the CYP21A2 gene, including point mutations (including small 
deletions and insertions), large gene deletions (approximately 30 kb) and large gene conversions. Haplotype-based 
linkage analysis is a promising method to overcome these complications. Our results showed that the developed 
method enabled us to analyze different types and locations of mutations in the same process.
As an indirect prenatal genetic test, a haplotype-based imbalance analysis for NIPT is limited by the presence 
of recombination event between target gene and SNP markers. Therefore, there is an indispensable requirement 
in the test in order to detect recombination events and avoid incorrect prediction. In a recent study, Yoo et al. 
performed a haplotype-based approach for NIPT of DMD after examining and correcting for the recombination 
event11. In one of their families, they identified a recombination event. Although the inherited fetal genotype 
could be correctly predicted, the approach couldn’t differentiate whether the recombination event occur in the 
proband or in the new fetus. The authors pointed out that the approach may be biased by false-recombination 
prediction because informative SNVs might be limited in number and located at greater distance. In our previous 
study, we constructed the standard haplotype using trio analysis with the SNP genotypes of the parents and amni-
otic fluid cells13. To test the accuracy of the inferred fetal haplotype, we compared the inferred paternal alleles and 
maternal alleles with the standard haplotypes. In the proband-assisted haplotype phasing (PAHP) process, the 
Haplotype
Expected 
depth
Accuracy of fetal haplotype inference
1% fetal DNA 
fraction
2% fetal DNA 
fraction
3% fetal DNA 
fraction
4% fetal DNA 
fraction
10% fetal DNA 
fraction
Maternal haplotype
30x — 100.00% 100.00% 100.00% 100.00%
50x — 100.00% 100.00% 100.00% 100.00%
100x 0 100.00% 100.00% 100.00% 100.00%
150x 0 100.00% 100.00% 100.00% 100.00%
200x 0 100.00% 100.00% 100.00% 100.00%
Paternal haplotype
30x — 100.00% 100.00% 100.00% 100.00%
50x — 100.00% 100.00% 100.00% 100.00%
100x 100.00% 100.00% 100.00% 100.00% 100.00%
150x 100.00% 100.00% 100.00% 100.00% 100.00%
200x 100.00% 100.00% 100.00% 100.00% 100.00%
Table 2. Effect of fetal DNA fraction and sequencing depth on the accuracy of the fetal haplotype inference in 
artificial mixtures.
Plasma 
sample
Fetal 
sex
Fetal DNA 
fraction
Paternal 
informative SNP
Maternal 
informative SNP P-Hap M-Hap Fetal genotype
Fetal 
status
F-01 F 11.08% 769 866 F0 M1 Del/WT carrier
F-02-F F 6.88% 830 534 P0 M0 IVS2-13A/C > G/Del affected
F-02-S F 9.49% 831 534 P0 M1 Del/WT carrier
F-03 F 5.50% 675 818 P0 M1 IVS2-13A/C > G/WT carrier
F-04 8wk F 7.82% 648 1330 P0 M0 p.Ile172Asn/Chimera affected
F-04 18wk F 8.15% 649 1330 P0 M0 p.Ile172Asn/Chimera affected
F-05 M 8.41% 545 620 P0 M0 IVS2-13A/C > G + promoter conversion/Del affected
F-06 M 14.28% 800 1024 P0 M1 Del/WT carrier
F-07 F 9.28% 477 640 P0 M1 Del/WT carrier
F-08 F 5.84% 524 841 P1 M0 p.Ile172Asn/WT carrier
F-09 M 12.00% 583 806 P0 M0 IVS2-13A/C > G/p. [Ile172Asn; Arg356Trp] affected
F-10 M 13.18% 620 829 P1 M0 Del/WT carrier
F-11 M 15.54% 814 715 P0 M0 p.[Gln318X; Arg356Trp]/Chimera affected
F-12 F 8.61% 393 711 P0 M0 IVS2-13A/C > G/Partial conv affected
Table 3. Determination of fetal sex, fetal DNA fraction, and fetal haplotype in each family. Abbreviantions: 
Paternal informative SNP: SNP that was uniquely identified in one paternal haplotype; Maternal informative 
SNP: SNP that was uniquely identified in one maternal haplotype; Pat-Hap, paternal inherited haplotype; 
Mat-Hap, maternal inherited haplotype; P0, paternal haplotype linked with pathogenic mutation; P1, paternal 
haplotype linked with wild-type allele; M0, maternal haplotype linked with pathogenic mutation; M1, maternal 
haplotype linked with wild-type allele; WT: wild-type allele.
www.nature.com/scientificreports/
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result showed that 1,862 paternal alleles and 4,692 maternal alleles were incorrectly phased in terms of a total of 
146,103 phased SNP sites. We found 30.12% of the error in the paternal haplotype and 23.66% of the errors in the 
maternal haplotypes occurred around recombination points. In addition, the PAHP strategy has a lower accuracy 
as compared with the grandparent-assisted haplotype phasing strategy. How to accurately infer the fetal inherited 
allele for recombination cases still need the improvement in technology and strategy. To overcome this shortcom-
ing, we restricted the SNP within 2 Mbp genomic region flanking the CYP21A2 gene to decrease the possibility of 
the observation of recombination events. The number of informative SNP is another critical factor that influences 
the accuracy of our method, we captured 1607 highly heterozygous SNPs to guarantee the available of enough 
Figure 2. Fetal inheritance of haplotype in families 1 to 12 involving CYP21A2. Haplotypes are shown within 
2 Mbp genomic region flanking the CYP21A2 gene. The inheritance of paternal haplotype is illustrated on the 
left, and the inheritance of maternal haplotpe is shown on the right. Hap 0 is linked to pathogenic mutations 
in the CYP21A2, while Hap 1 is linked to wild-type allele. The black lines indicate haplotype inheritance by 
the fetus. The logarithmic odds ratio of transmission probability between Hap 0 and Hap 1, and is calculated 
by P0*P0re/(P1*P1re), where P0re is the probability of recombination involving fetal inheritance of Hap 0, 
and P1re is the probability of recombination involving fetal inheritance of Hap 1. The purple line indicates the 
region of CYP21A2.
www.nature.com/scientificreports/
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informative SNP for each sample (Supplemental Table S5). The small region and high density of highly heterozy-
gous SNPs make the analysis method more accurate and reliable for implementation into clinical practice.
In our study, the parental haplotypes were constructed by using trio analysis based on Mendel’s Law of 
Segregation. However, the approach is contingent on the availability of DNA from an affected proband and access 
to specialist facilities with sufficient experience in bioinformatic prediction. These requirements might be difficult 
to fulfill in certain circumstances. A newly developed technology, microfluidics-based linked-read sequencing, 
enables the rapid genome wide phasing using a process of microdroplet barcoding of long DNA molecules19. 
Recently, the direct haplotyping technology was first applied in NIPT of single gene diseases20. Thirteen families 
at risk for a fetus with CAH, β-thalassemia, Ellis-van Creveld syndrome, hemophilia or Hunter syndrome were 
recruited for the study. Utilizing microfluidics-based linked-read sequencing followed by maternal plasma-based 
RHDO analysis, the mutational status of these 12 fetuses was correctly deduced. The investigators demonstrated 
that the approach enabled streamline NIPT of single gene diseases without the need to design tailor-made 
mutation-specific assays and only required the use of specimens from the parents20. This represents further pro-
gress in the study of NIPD of single gene diseases.
The determination of fetal sex facilitates the prognosis of CAH, and also plays a key role in several monogenic 
diseases. By adding chromosome Y-specific region to the same capture assay, the fetal sex is determined in a sin-
gle step. Our results show a significant difference in the coverage and mean depth of chromosome Y between the 
plasma samples collected from pregnant women with female and male fetuses. Female foetus was associated with 
very low parameters, which might be caused by non-specific mapping of the reads, to noninvasively distinguish 
female from male fetuses. The fetal sex was correctly determined in our study.
Expanding the NIPT of 21-OHD to early gestation is meaningful for clinical application. It facilitates compre-
hensive evaluation by parents and physicians to decide appropriate clinical interventions. In view of the introduc-
tion of NIPT-based tests into early gestational application, the fetal DNA fraction is a key parameter governing 
the analytical performance. In such haplotype-based approaches11–14, 17, 18, the influence of fetal DNA on the 
accuracy of NIPT has not been clarified by using an experimental protocol. We performed a series of simulation 
experiments to investigate the role of fetal DNA in NIPT of 21-OHD and parameters that might improve the 
sensitivity of our method. The results showed that at a mean sequence depth of plasma of 39×, the fetal genotype 
was successfully determined from plasma samples using a fetal DNA fraction of 2%. Most pregnancies show a 
fetal DNA fraction higher than 4%, suggesting that our method was applicable for use in most pregnancies21. We 
used four early gestation plasma samples (F-02-F, F-07, F-09, and F-10), with a gestation age ranging from 8 wk 
1 d to 12 wk 2 d. The fetal DNA fraction of these samples ranged from 5.84% to 13.18%, and the genotype of these 
four samples was correctly determined. In our study, the fetal DNA fraction of early gestation plasma was not sig-
nificantly lower than the samples collected during the second trimester, which might be attributed to individual 
differences and small sample size21.
In conclusion, we found that NIPD of 21-OHD based on sequencing of small targeted regions was 
cost-effective for routine clinical application. We also determined the limitations of fetal DNA fraction and 
sequencing depth, which indicate that our method favored analysis during early gestation and laid the foundation 
for further prospective studies.
Methods and Materials
Case recruitment. Twelve families diagnosed with CAH were recruited at the Department of Prenatal 
Diagnosis in Nanjing Maternity and Child Health Care Hospital (Jiangsu, China) between 2014 and 2015. A 
blood sample was collected from each pregnant woman, her husband, and their first child, and placed into tubes 
with EDTA to prevent coagulation. Maternal plasma was separated from the blood sample within 8 h. Amniotic 
fluid samples were obtained through amniocentesis at 18 to 22 weeks of gestation for routine prenatal diagno-
sis. In plasma DNA analysis, the CYP21A2 mutations in fetuses were blinded to data analyst engineers. During 
routine prenatal diagnosis, multiplex ligation-dependent probe amplification (MLPA) and Sanger sequencing 
were used to identify CYP21A2 mutations as previously described22, 23. Parental informed consent was obtained 
to perform extensive molecular studies. The present study was conducted in accordance with the Declaration of 
Helsinki, and was approved by the Ethics Committee of Nanjing Maternity and Child Health Care Hospital (No. 
[2014] 61).
Capture sequencing. Cell-free DNA (cf-DNA) was extracted from 1.2 mL samples of maternal plasma using 
QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany), and quantified using Qubit 2.0 fluorometer 
(Invitrogen by Life Technologies, Carlsbad, CA, USA). A pre-hybridization library was prepared using the KAPA 
library preparation Kit (KAPA Biosystems, Wilmington, MA, USA). According to the manufacturer’s protocol, 
10–20 ng cf-DNA was used for library preparation. After end-repair and “A”-overhanging, adapters were ligated 
to the DNA fragment, and the library was enriched and labeled with index primers in eight cycles of PCR. The 
pre-hybridization library of genomic DNA (gDNA) was prepared according to the Illumina standard protocol. 
Briefly, 1 μg genomic DNA was sonicated to yield DNA fragments with an average size of 200 bp to 250 bp. After 
end-repairing and “A”-overhanging, the adapters were ligated to the fragments, and the library was enriched and 
labeled with index primers through 4 to 5 cycles of PCR. The gDNA and plasma DNA libraries were captured 
using the same custom-designed NimbleGen SeqCap EZ probes (Roche NimbleGen, Madison,WI, USA) with a 
target region of 274.15 kb, including CYP21A2, 1607 highly heterozygous SNPs distributed within 2 Mbp genomic 
region flanking the CYP21A2 gene and 13.3 kb chromosome Y-specific region. All the enriched libraries were 
paired-end sequenced using Illumina Hiseq. 2500 (Illumina, San Diego, CA, USA) with a read length of 101 bp.
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Sequence alignment and SNP calling. The low quality reads were removed using SOAPnuke Software 
parameter -l 10 -q 0.5 -n 0.1. The BWA software (0.7.12) was used to align reads to the human reference genome 
(Hg19, GRCh37). The variants in the genomic DNA samples were determined using GATK software, and the low 
quality reads were filtered out using GATK Variant Filtration (filterExpression “QD < 2.0 || MQ < 40.0 || FS > 60.0 || 
Haplotype Score > 13.0 || MQ Rank Sum < −12.5 || ReadPos Rank Sum < −8.0”). For plasma DNA sample, a pipe-
line reported by Garrett M Frampton24 was modified to detect variants with allele ratio greater than 1%. Briefly, low 
quality reads with mapping quality less than 13 or base quality less than 13 were discarded. The PCR duplication 
reads were marked and removed using Picard (1.87). The variants with an allele ratio greater than 1% were deter-
mined by Bayesian methodology, the strand bias was filtered using Fisher’s test (P < 1e-4) and the read location 
bias was filtered using Kolmogorov-Smirnov test (P < 1e-6). We also filtered out sites covered by less than 40 reads.
Calculation of fetal DNA fraction. The fetal DNA fraction was calculated using SNPs with different paren-
tal homozygosity, using the following formula:
=
∑ +f
n (1)
i
n p
p q
2
( )
i
i i
where pi denotes the number of paternal specific alleles and qi is the number of maternal alleles in the plasma 
sample, and n is the number of SNPs using fetal DNA fraction.
Determination of the fetal sex. Plasma samples of male fetus showed higher mean depth of target region 
on chromosome Y and 4× coverage than in female fetus. Thus, the fetal sex was determined according to the 
mean depth and 4× coverage of the 13 kb chromosome Y-specific region.
Noninvasive prenatal detection of fetal CYP21A2 genotype. Base on the trios’ strategy17, 18, the 
parental haplotypes and their linkage to 21-OHD were established using SNPs identified in the CYP21A2 gene 
and its flanking region in the parents and the child. We defined haplotype 0 (Hap 0) as the haplotype linked 
to the pathogenic mutation, and haplotype 1 (Hap 1) as the haplotype linked to the wild-type allele. Paternal 
inheritance was determined using SNPs heterozygous in father but homozygous in mother. Maternal inher-
itance was determined using SNPs that were heterozygous in mother but homozygous in father. We defined 
haplotype-informative SNP as SNP that was uniquely identified in one haplotype, and not in the other three hap-
lotypes. Informative SNPs linked to the inherited haplotype are over-represented in the plasma. We constructed a 
hidden Markov model (HMM)17, 25 to determine the inheritance of parental haplotype from plasma data.
Briefly, for each SNP, the observed state was denoted as S = {Nj}, where Nj = {Pos, Fgt, Mgt, Pgt, dep_ref, 
dep_alt}, and Pos, Fgt, Mgt, Pgt, dep_ref, dep_alt denote position, paternal genotype, maternal genotype, child’s 
genotype, the number of reads supporting the reference allele and non-reference allele, respectively.
The hidden state was defined as the pathogenic haplotype (Hap 0) inherited by the fetus, and was denoted as 
Q = {Hap 0, Hap 1}. Because of the lack of prior probability, we defined the initial state distribution as π = {1/2, 
1/2}.
The emission probabilities matrix is represented by B = {bi,j}, bi,j = P{Hap i|Nj}, i ∈{0, 1}, j = 1, 2, 3, …, n. The 
probability of Hap i-rich SNP transmitted to the fetus at a given site j was calculated as follows:
| =
| × .
| × | × .
P Hapi N
P N Hapi
P N Hap P N Hap
{ }
{ } 0 5
{ 0} { 1} 0 5 (2)
j
j
j j
P{Nj | Hap 0} and P{Nj | Hap 1} were calculated using binomial distribution:
=P{Nj Hap 0} b(k, n, prob0) (3)
= k nP{Nj Hap 1} b( , , prob1) (4)
P{Nj| Hap i} is the probability of the observed state Nj at a given SNP loci j in the plasma when Hap i was trans-
mitted to the fetus, k denotes the reads of the haplotype-rich allele, n refers to the total reads at a given site, prob0 
and prob1 represent the expected proportion of Hap 0 infomative allele and Hap 1 informative alleles calculated 
according to fetal DNA fraction, respectively, as illustrated in Supplemental Table S1.
The transition probabilities matrix was denoted as A = {aj}, where
=



−
−



a
P P
P P
1
1 (5)
j
j
j j
j
and Pj is the probability of recombination between two neighboring SNPs calculated by the genetic distance 
determined using the hapmap.
Finally, the Viterbi algorithm26 was used to determine the optimal path through the observed data and deduce 
the inheritance of maternal haplotype and paternal haplotype, respectively:
∑= ×
∈
+ +Path i a[ ] ln( max b ( )) (6)j
n
r
i j i r j
(0,1)
, 1, 1,
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Role of fetal DNA fraction and sequencing depth in NIPT. To determine the effect of fetal DNA frac-
tion and sequencing depth on the accuracy of NIPT, we performed experiments using a series of artificial sam-
ples of fetal gDNA diluted to paired maternal gDNA. Briefly, the maternal gDNA and fetal gDNA of case 2′ first 
pregnancy were fragmented to ~200 bp using sonicator. Double size selection of fragments was performed using 
SPRIselect beads (Beckman Coulter Genomics, Danvers, MA, USA) to recover fragment size 100–300 bp accord-
ing to the manufacturer’s protocol. After quantification using Qubit (Invitrogen by Life Technologies), fetal gDNA 
and maternal gDNA were combined to create artificial plasma samples of 1%, 2%, 3%, 4%, and 10% fetal DNA 
fractions (w/w). Sequencing libraries were prepared using the same protocol as real plasma sample, and sequenced 
with pair-ended 101 bp reads using HiSeq. 2500 (Illumina). To investigate the effect of sequencing depth on the 
accuracy of NIPT, for each artificial plasma sample, we simulated a series of sequencing depths at 30×, 50×, 100×, 
150×, and 200× by randomly sampling different numbers of mapped reads. The simulated data were analyzed 
using our NIPT method. The accuracy of our method was determined by comparing the deduced fetal haplotype 
of CYP21A2 and the flanking SNPs with that of the standard haplotype deduced from fetal genomic DNA.
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